FDA advisory panel considers cardiovascular and teratogenic risks of Vivus’ weight-loss drug Qnexa.
Dermatologic & Ophthalmic Drugs Advisory Committee to discuss problems with cross-contamination from eye droplet bottles on Feb. 27.
Ceptaris Therapeutics, which changed its name from Yaupon Therapeutics in January, has raised $15 million in a debt financing. It will use the money to continue advancing Clearazide – a topical gel formulation of a generic chemotherapeutic – for early-stage cutaneous T-cell lymphoma.
Mylan revealed at an investor day on Feb. 21. that it plans to enter the biosimilars market with generic versions of several oncologic products.
